HIV-1 isolates with reduced susceptibility to the combination of emtricitabine and tenofovir have been selected in vitro. Genotypic analysis of these isolates identified the M184V/I and/or K65R amino acid substitutions in the viral reverse transcriptase.
The safety and efficacy of emtri-citabine and tenofovir as combination therapy have not been extensively covered in the literature. As monotherapy, however, each agent has been shown to be effective in the treatment of HIV infection.
The goal of antiretroviral therapy is to preserve the immune system by disrupting the viral cell cycle. The two agents in Truvada™ prevent HIV from replicating and, as a result, help protect the immune system. One tablet is bio-equivalent to one 200-mg Emtriva® capsule plus one 300-mg Viread® tablet (equivalent to 245 mg of tenofovir […]
INTRODUCTION Acquired immunodeficiency syndrome (AIDS) is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV). The retrovirus and the infection itself are known as HIV. The term AIDS is used to describe the later stages of HIV infection.